TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024

Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.

Collin M Blakely et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.